DYV-024 Clin0 psoriasis; DYV-800 Clin0 solid tumors
Dyve Biosciences is developing technology that can utilize the skin as a delivery modality to treat immunologic and oncologic diseases. During tumorigenesis the microenvironment often becomes acidic further driving cancer cell invasiveness. Dyve is addressing this acidity by leveraging their DMAX transdermal platform to deliver intuitive, targeted pH modulation to increase the pH and reverse the conditions that lead to disease progression. Dyve’s lead products, DYV800 and DYV700, are systemically bioavailable and seek out locally acidic microenvironments. The transdermal delivery circumvents the drug passing through the acidic gastrointestinal tract making Dyve’s approach innovative and intuitive.